Technology Platform
Translating genetic discoveries into cures is rapidly becoming reality
It is designed to utilize AAVHSCs to deliver therapeutic DNA for heavy chain and light chain antibody proteins that are delivered to the liver where they form fully functional, full-length Immunoglobulin G (IgG) antibodies and are secreted throughout the body.
Our approach with the GTx-mAb platform unlocks the potential to expand our pipeline to address complement-related disorders and diseases with larger patient populations.
GTx-mAb
